<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Fisher G</submitter><funding>Cancer Research UK</funding><funding>NCI NIH HHS</funding><pagination>271-7</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3566811</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>108(2)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Standard clinical parameters cannot accurately differentiate indolent from aggressive prostate cancer. Our previous work showed that immunohistochemical (IHC) Ki-67 improved prediction of prostate cancer death in a cohort of conservatively treated clinically localised prostate cancers diagnosed by transurethral resection of the prostate (TURP). Here, we present results in a more clinically relevant needle biopsy cohort.&lt;h4>Methods&lt;/h4>Biopsy specimens were microarrayed. The percentage of Ki-67 positively stained malignant cells per core was measured and the maximum score per individual used in analysis of time to death from prostate cancer using a Cox proportional hazards model.&lt;h4>Results&lt;/h4>In univariate analysis (n=293), the hazard ratio (HR) (95% confidence interval</pubmed_abstract><journal>British journal of cancer</journal><pubmed_title>Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.</pubmed_title><pmcid>PMC3566811</pmcid><funding_grant_id>P30 CA008748</funding_grant_id><pubmed_authors>Kudahetti S</pubmed_authors><pubmed_authors>Transatlantic Prostate Group</pubmed_authors><pubmed_authors>Yang ZH</pubmed_authors><pubmed_authors>Scardino P</pubmed_authors><pubmed_authors>Fisher G</pubmed_authors><pubmed_authors>Berney DM</pubmed_authors><pubmed_authors>Moller H</pubmed_authors><pubmed_authors>Cuzick J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.</name><description>&lt;h4>Background&lt;/h4>Standard clinical parameters cannot accurately differentiate indolent from aggressive prostate cancer. Our previous work showed that immunohistochemical (IHC) Ki-67 improved prediction of prostate cancer death in a cohort of conservatively treated clinically localised prostate cancers diagnosed by transurethral resection of the prostate (TURP). Here, we present results in a more clinically relevant needle biopsy cohort.&lt;h4>Methods&lt;/h4>Biopsy specimens were microarrayed. The percentage of Ki-67 positively stained malignant cells per core was measured and the maximum score per individual used in analysis of time to death from prostate cancer using a Cox proportional hazards model.&lt;h4>Results&lt;/h4>In univariate analysis (n=293), the hazard ratio (HR) (95% confidence interval</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013 Feb</publication><modification>2025-04-04T10:11:59.281Z</modification><creation>2019-03-27T01:04:29Z</creation></dates><accession>S-EPMC3566811</accession><cross_references><pubmed>23329234</pubmed><doi>10.1038/bjc.2012.598</doi></cross_references></HashMap>